CeaproTSXV: CZO

Ceapro Inc. appoints VP Business Development

· Issued by Ceapro via CNW

EDMONTON, May 31 /CNW/ - Ceapro Inc. (CZO - TSX Venture) ("Ceapro" or the "Corporation") today announced the appointment of Ian W. Cottrell, Ph.D as Vice President Business Development.

Ian Cottrell is an experienced executive with extensive business acumen and technological expertise, having worked with both established and entrepreneurial profit centers spanning North America, Europe and the Pacific Rim. He has experience in establishing and aligning business, marketing and technology strategies, and a record of developing revenues and cost savings from new product and process development. His expertise is based on over 30 years' experience in specialty chemical, biotechnology and consumer products.

Most recently, Ian Cottrell was responsible for the development of specialty pet products for the Animal Health and Grooming categories at The Hartz Mountain Corporation. Dr Cottrell received his Ph.D. in organic chemistry from the University of Edinburgh, Scotland.

"Ceapro has devoted time and significant brain power to developing its core competencies. Of late, a number of consumer products have come of this investment and it is time to have an executive devoted to business development. Dr Cottrell's addition to the Ceapro team gives our company depth of experience and expertise in that realm," said Dr. Mark Redmond, the Corporation's President and CEO. "His specific knowledge as well as his significant market experience will help bring Ceapro to the next level of commercialization success."

About Ceapro Inc.

Ceapro Inc is a Canadian growth-stage biotechnology company. Ceapro's core technology is the extraction of functional, active ingredients from plants and other renewable resources. We add further value to our extracts by manufacturing medical and therapeutic products, and by supporting the use of our extracts in products for human and animal health. We have also introduced health and wellness services employing our CeaProve(R) diagnostic technology. Our most recent initiative is the creation of Ceapro BioEnergy Inc. (CBE), a wholly-owned subsidiary to utilize Ceapro's proprietary technology for the production of ethanol and value-added products. Ceapro shares trade on the Canadian TSX Venture Exchange under the symbol CZO. To learn more about Ceapro, visit our website at www.ceapro.com.

The TSX has neither approved nor disapproved of the information contained

herein -

This release may contain forward-looking statements. Various factors could cause actual results to differ materially from those projected in forward-looking statements. Although the Company believes that the forward-looking statements contained herein are reasonable, it can give no assurance that the Company's expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

%SEDAR: 00010110E

Ceapro on 6ix

Earlier from Ceapro

Later from Ceapro

All Ceapro news releases